HRMY, US4131971040

Harmony Biosciences stock faces November 4 earnings catalyst

Published on 11/03/2026 at 00:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harmony Biosciences stock has a scheduled earnings event on November 4. Investors will get an update on WAKIX sales and the rare-neurology pipeline.

What HRMY Investors Should Watch

Harmony Biosciences will release third-quarter 2026 results before US markets open on November 4.
Management will discuss the results during an 8:30 a.m. Eastern Time conference call.
WAKIX remains the commercial base while BP-205 and additional pitolisant formulations support the pipeline.

HRMY, US4131971040, Illustration mit AI erstellt.

Harmony Biosciences will report its third-quarter 2026 financial results before the US financial markets open on Wednesday, November 4, the company said in a release carried by StockTitan. Management plans to discuss the figures during a conference call and webcast at 8:30 a.m. Eastern Time.

Earnings Set The Near-Term Focus

The release will give investors a fresh view of demand for WAKIX, Harmony's approved treatment for excessive daytime sleepiness in adults with narcolepsy. The company previously reiterated 2026 WAKIX net revenue guidance of 1.0 billion to 1.04 billion US dollars, according to the company's October 12 announcement as reproduced by StockTitan.

Analysts are also watching whether the commercial franchise can maintain its growth rate while Harmony expands into additional neurological indications. A Yahoo Finance analysis said WAKIX generated 476.7 million US dollars in sales during the first half of 2026 and highlighted planned gastro-resistant and high-dose pitolisant formulations.

Pipeline Milestones Add Risk

Harmony is advancing BP-205, an investigational orexin-2 receptor agonist, with multiple-ascending-dose study data expected in the fourth quarter of 2026. The pipeline could broaden the company's sleep-medicine franchise, but future commercial impact remains dependent on clinical and regulatory outcomes.

Investors should therefore focus on WAKIX prescription and revenue trends, management's comments on the 2026 outlook, and the timing of upcoming development milestones. The earnings call may also clarify how the company plans to balance commercial investment with pipeline spending.

Specialized Rare-Neurology Business

Harmony Biosciences is a US pharmaceutical company focused on developing and commercializing treatments for rare neurological diseases, with WAKIX as its commercial product and a pipeline spanning sleep-wake disorders and other neurological conditions. It is headquartered in Plymouth Meeting, Pennsylvania. In narcolepsy, the company competes with broader sleep-medicine businesses such as Jazz Pharmaceuticals, which markets Xywav, and Alkermes, which markets Lumryz, while Harmony remains more concentrated on its WAKIX-led rare-neurology strategy.